Background: Ulcerative colitis (UC) is a chronic condition and the most common form of inflammatory bowel disease. The goal of standard treatment is mainly to induce and maintain remission with anti-inflammatory, immunosuppressive agents, and/or colectomy. Fecal microbiota transplantation (FMT) has been used successfully to treat relapsing or refractory Clostridium difficile infection. The alteration of microbiota in mouse models of UC as well as in patients suggested the possibility of treating UC with FMT.
Aims: To study the effects of FMT on dextran sodium sulfate (DSS)-induced UC model in mice.
Methods: Littermates of BALB/c and C57BL/6J were randomized into four groups: normal control , treatment with DSS for 7 days (DSS - FMT), treatment with DSS followed by FMT for another 8 days (DSS + FMT), and treatment with DSS and FMT followed by another 5 days for recovery (remission). Body weight, survival rate, and DAI scores of mice in each group were recorded. Changes in distal colon were studied by histopathology. Alterations of spleen and lamina propria regulatory lymphocytes, major bacterial species in feces and inflammatory cytokines in colon were also studied.
Results: C57BL/6J mice experienced more significant weight loss than BALB/c mice after DSS treatment, regardless of whether the two strains of mice were co-housed or not. FMT caused reversal of DAI scores in BALB/c but not in C57BL/6J mice. In BALB/c mice, FMT also reduced colon inflammation that was paralleled by decreased inflammatory cytokine levels, altered bacterial microbiota, and regulatory lymphocyte proportions.
Conclusions: FMT is effective in a mouse model of UC through its modulation on gut microbiota and the host immune system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10620-016-4060-2 | DOI Listing |
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose: To evaluate the prognosis of eyelid sebaceous carcinoma (SeC) in patients with disease stage worse than IIA.
Methods: This retrospective, single-center study included 78 SeC patients. For stage II patients, 1:3 propensity score matching (PSM) was applied between those undergoing orbital exenteration and those receiving eye-sparing treatments.
Anim Microbiome
January 2025
Institute of Animal Nutrition, Sichuan Agricultural University, Chengdu, Sichuan, 611130, P.R. China.
Background: A. muciniphila (AKK) has attracted extensive research interest as a potential next-generation probiotics, but its role in intestinal pathology is remains unclear. Herein, this study was conducted to investigate the effects of A.
View Article and Find Full Text PDFAm J Physiol Gastrointest Liver Physiol
January 2025
Department of Physiology and Pharmacology, Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada.
Mucosal healing is the primary goal for Inflammatory Bowel Diseases (IBD) treatment. We previously showed the direct beneficial effects of rhamnogalacturonan (RGal) on intestinal epithelial barrier function. Here, we aimed to evaluate the effect of RGal in intestinal epithelial wound healing.
View Article and Find Full Text PDFHead Neck
January 2025
Head and Neck Oncology Department, Tata Memorial Hospital and HBNI, Mumbai, India.
Background: The current classification of tongue cancers does not discriminate stages based on factors of local spread.
Aim: Integrating factors of local spread that impact disease-specific survival (DSS) in a modified classification to improve prognostication compared with the current staging.
Method: This was a retrospective analysis of 399 previously untreated oral tongue squamous carcinomas operated between 2016 and 2018.
Adv Sci (Weinh)
January 2025
Collaborative Innovation Center for Clinical and Translational Science, Department of Pharmacology and Chemical Biology, & Institute of Molecular Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, P. R. China.
Inflammatory bowel disease (IBD) is characterized by intestinal mucosal damage that exacerbates inflammation and promotes disease recurrence. Although hydrogel-based therapies have shown potential for mucosal repair, challenges remain due to inadequate targeting and low hydrogel density, leading to ongoing infiltration of harmful substances and delayed mucosal healing. In this study, an inflammation-targeting-triggered healing hydrogel (ITTH hydrogel) is developed, composed of polyvinyl alcohol-alginate microgels (PALMs) and a cyclodextrin polymer crosslinker (CPC).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!